drugset / Trial / NCT07221851

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

NCT07221851

Phase 3 Recruiting 186 enrolled Ascendis Pharma A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This basket trial will enroll prepubertal children and adolescents with clinically diagnosed and genetically confirmed (if applicable) TS, SHOX-D, SGA, or ISS between ages of ≥2 and \<18 years with open growth plates. The purpose of the study is to see how well treatment with once-weekly lonapegsomatropin works compared to treatment with daily somatropin. Approximately 186 participants will be distributed equally (1:1), to receive either lonapegsomatropin for 2 years or somatropin for 1 year followed by lonapegsomatropin for 1 year. This trial will be conducted in the United States, France, Germany, Italy, Romania, Spain and South Korea.

Timeline

Start
2025-12-12
Primary completion
2028-02
Completion
2029-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Lonapegsomatropin Protein / enzyme biologic Subcutaneous
Subject Somatropin Protein / enzyme biologic Subcutaneous